This treatment was well tolerated with only temporary CNS inflammation reported, despite only two patients exhibiting anti-tumour responses, either through reduced IL13Rα2 expression or an increased necrotic tumour volume at delivery site [151]. This evidence concerns the gene IL13RA2 and neoplasm.